These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35182586)

  • 1. Comparison of Selective vs Empiric Pharmacologic Preventive Therapy of Kidney Stone Recurrence With High-Risk Features.
    Hsi RS; Yan PL; Crivelli JJ; Goldfarb DS; Shahinian V; Hollingsworth JM
    Urology; 2022 Jun; 164():74-79. PubMed ID: 35182586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Empiric Preventative Pharmacologic Therapies on Stone Recurrence Among Patients with Kidney Stone Disease.
    Hsi RS; Yan PL; Crivelli JJ; Goldfarb DS; Shahinian V; Hollingsworth JM
    Urology; 2022 Aug; 166():111-117. PubMed ID: 35545149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Effectiveness of Preventive Pharmacological Therapy in Patients With Urolithiasis: A Retrospective Cohort Study.
    Hollingsworth JM; Oerline MK; Hsi RS; Crivelli JJ; Krampe N; Asplin JR; Shahinian VB
    Am J Kidney Dis; 2024 Jul; 84(1):83-93.e1. PubMed ID: 38432593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Selective Versus Empiric Pharmacologic Preventative Therapy With Kidney Stone Recurrence.
    Hsi RS; Yan PL; Goldfarb DS; Egbuji A; Si Y; Shahinian V; Hollingsworth JM
    Urology; 2021 Mar; 149():81-88. PubMed ID: 33352163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations Between Provider Specialty and Use of Follow-up Testing Among Patients on Preventive Pharmacological Therapy for Urinary Stone Disease.
    Crivelli JJ; Yan PL; Shahinian V; Hsi RS; Hollingsworth JM
    Urol Pract; 2023 Jul; 10(4):400-406. PubMed ID: 37341368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventive Pharmacological Therapy and Risk of Recurrent Urinary Stone Disease.
    Arivoli K; Valicevic AN; Oerline MK; Hsi RS; Patel SR; Hollingsworth JM; Shahinian VB
    Clin J Am Soc Nephrol; 2024 May; 19(5):565-572. PubMed ID: 38345854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the Barriers to Preventive Pharmacological Therapy Use in Older Patients With Urinary Stone Disease.
    Krampe N; Oerline MK; Hsi RS; Crivelli JJ; Asplin JR; Shahinian VB; Hollingsworth JM
    Urol Pract; 2024 Jan; 11(1):218-225. PubMed ID: 37903744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twenty-four-hour Urine Testing and Urinary Stone Disease Recurrence in Veterans.
    Song S; Thomas IC; Ganesan C; Velaer KN; Chertow GM; Pao AC; Leppert JT
    Urology; 2022 Jan; 159():33-40. PubMed ID: 34688771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twenty-Four Hour Urine Testing and Prescriptions for Urinary Stone Disease-Related Medications in Veterans.
    Song S; Thomas IC; Ganesan C; Sohlberg EM; Chertow GM; Liao JC; Conti S; Elliott CS; Pao AC; Leppert JT
    Clin J Am Soc Nephrol; 2019 Dec; 14(12):1773-1780. PubMed ID: 31712387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medication Nonadherence and Effectiveness of Preventive Pharmacological Therapy for Kidney Stones.
    Dauw CA; Yi Y; Bierlein MJ; Yan P; Alruwaily AF; Ghani KR; Wolf JS; Hollenbeck BK; Hollingsworth JM
    J Urol; 2016 Mar; 195(3):648-52. PubMed ID: 26485048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors Associated With Preventive Pharmacological Therapy Adherence Among Patients With Kidney Stones.
    Dauw CA; Yi Y; Bierlein MJ; Yan P; Alruwaily AF; Ghani KR; Wolf JS; Hollenbeck BK; Hollingsworth JM
    Urology; 2016 Jul; 93():45-9. PubMed ID: 27041472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of the 24-Hour Urine Collection in the Prevention of Kidney Stone Recurrence.
    Hsi RS; Sanford T; Goldfarb DS; Stoller ML
    J Urol; 2017 Apr; 197(4):1084-1089. PubMed ID: 27746283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for subsequent stone events in pediatric nephrolithiasis: A multi-institutional analysis.
    Medairos R; Paloian NJ; Pan A; Moyer A; Ellison JS
    J Pediatr Urol; 2022 Feb; 18(1):26.e1-26.e9. PubMed ID: 34980558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Class-Specific Side Effects Across Preventative Pharmacologic Therapies for Kidney Stone Disease.
    Hsi RS; Crivelli JJ; Yan PL; Shahinian V; Hollingsworth JM
    Urol Pract; 2024 Jan; 11(1):172-178. PubMed ID: 38117963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term prescription of α-blockers decrease the risk of recurrent urolithiasis needed for surgical intervention-a nationwide population-based study.
    Liu CC; Hsieh HM; Wu CF; Hsieh TJ; Huang SP; Chou YH; Huang CN; Wu WJ; Wu MT
    PLoS One; 2015; 10(4):e0122494. PubMed ID: 25875226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic Work-up of Patients with Urolithiasis: Indications and Diagnostic Algorithm.
    Tiselius HG; Daudon M; Thomas K; Seitz C
    Eur Urol Focus; 2017 Feb; 3(1):62-71. PubMed ID: 28720369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of Clinical Microbiome Studies in Urolithiasis Reveal Age, Stone Composition, and Study Location as the Predominant Factors in Urolithiasis-Associated Microbiome Composition.
    Kachroo N; Lange D; Penniston KL; Stern J; Tasian G; Bajic P; Wolfe AJ; Suryavanshi M; Ticinesi A; Meschi T; Monga M; Miller AW
    mBio; 2021 Aug; 12(4):e0200721. PubMed ID: 34372696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Established and recent developments in the pharmacological management of urolithiasis: an overview of the current treatment armamentarium.
    Abou Chakra M; Dellis AE; Papatsoris AG; Moussa M
    Expert Opin Pharmacother; 2020 Jan; 21(1):85-96. PubMed ID: 31714803
    [No Abstract]   [Full Text] [Related]  

  • 19. Specialist Care, Metabolic Testing, and Testing Completeness Among U.S. Veterans with Urinary Stone Disease.
    Hsi RS; Valicevic AN; Patel SR; Oerline MK; Pao AC; Leppert JT; Hollingsworth JM; Shahinian V
    Urol Pract; 2023 Jan; 10(1):49-56. PubMed ID: 36545539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of 24-hour urine collection in high risk stone formers.
    Milose JC; Kaufman SR; Hollenbeck BK; Wolf JS; Hollingsworth JM
    J Urol; 2014 Feb; 191(2):376-80. PubMed ID: 24018242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.